• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[用淋巴因子激活的杀伤细胞进行恶性疾病的过继性免疫治疗]

[Adoptive immunotherapy of malignant diseases with LAK cells].

作者信息

Kimoto Y, Tanji Y, Tanaka T, Taguchi T

出版信息

Gan To Kagaku Ryoho. 1987 Mar;14(3 Pt 1):687-92.

PMID:3493732
Abstract

Peripheral blood lymphocytes obtained from patients by leukapheresis were cultured in RPMI 1640 containing human plasma and interleukin 2. The morphology, phenotypes and cytotoxicity of induced LAK cells were studied. Lymphoblastoid cells mainly proliferated were OKIa1+ cells and were thought to be LAK cells. Maximal cytotoxicity was obtained after two weeks of incubation. IL-2 enhanced the cytotoxicity of LAK cells. Autologous LAK cells induced by two weeks of incubation were injected into patients. One case of pulmonary metastases of breast cancer showed reduction and two lesions showed partial regression. Also, no new lesions appeared in the lungs of a patient with alveolar soft-part sarcoma.

摘要

通过白细胞分离术从患者获取的外周血淋巴细胞,在含有人类血浆和白细胞介素2的RPMI 1640培养基中培养。对诱导的LAK细胞的形态、表型和细胞毒性进行了研究。主要增殖的淋巴母细胞样细胞为OKIa1 +细胞,被认为是LAK细胞。孵育两周后获得最大细胞毒性。白细胞介素2增强了LAK细胞的细胞毒性。将孵育两周诱导的自体LAK细胞注入患者体内。1例乳腺癌肺转移患者的转移灶缩小,2个病灶部分消退。此外,1例肺泡软组织肉瘤患者的肺部未出现新病灶。

相似文献

1
[Adoptive immunotherapy of malignant diseases with LAK cells].[用淋巴因子激活的杀伤细胞进行恶性疾病的过继性免疫治疗]
Gan To Kagaku Ryoho. 1987 Mar;14(3 Pt 1):687-92.
2
[LAK cells and cancer].[淋巴因子激活的杀伤细胞与癌症]
Gan To Kagaku Ryoho. 1986 Dec;13(12):3327-33.
3
[Adoptive immunotherapy of cancer patients with lymphokine-activated killer cells].[应用淋巴因子激活的杀伤细胞对癌症患者进行过继性免疫治疗]
Gan To Kagaku Ryoho. 1987 Mar;14(3 Pt 2):914-21.
4
Adoptive immunotherapy of malignant diseases with IL-2-activated lymphocytes.用白细胞介素-2激活的淋巴细胞对恶性疾病进行过继性免疫治疗。
Biken J. 1987 Jun;30(2):29-38.
5
[Adoptive immunotherapy of malignant disease using LAK cells].[利用淋巴因子激活的杀伤细胞对恶性疾病进行过继性免疫治疗]
Gan To Kagaku Ryoho. 1988 Apr;15(4 Pt 2-1):788-96.
6
[Lymphokine-activated killer (LAK) adoptive immunotherapy: optimal method for large-scale LAK induction].[淋巴因子激活的杀伤细胞(LAK)过继性免疫疗法:大规模诱导LAK的最佳方法]
Gan To Kagaku Ryoho. 1987 Jun;14(6 Pt 1):1871-6.
7
The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo.淋巴因子激活的杀伤细胞和重组白细胞介素2在体内的抗肿瘤疗效。
J Immunol. 1985 Jul;135(1):646-52.
8
[Antimetastasis effect of lymphokine-activated killer (LAK) cells on fibrosarcoma in WKA rats].[淋巴因子激活的杀伤细胞(LAK细胞)对WKA大鼠纤维肉瘤的抗转移作用]
Zhonghua Zhong Liu Za Zhi. 1986 Nov;8(6):421-3.
9
Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer.对转移性癌症患者进行自体淋巴因子激活的杀伤细胞和重组白细胞介素-2全身给药的观察。
N Engl J Med. 1985 Dec 5;313(23):1485-92. doi: 10.1056/NEJM198512053132327.
10
[Clinical studies of adoptive immunotherapy of human disseminated brain tumors with LAK cells and recombinant interleukin-2].
No To Shinkei. 1986 Jun;38(6):593-8.